Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy

Open access
Kuter, David J., Bussel, James B., Newland, Adrian, Baker, Ross I., Lyons, Roger M., Wasser, Jeffrey, Viallard, Jean‐Francois, Macik, Gail, Rummel, Mathias, Nie, Kun, Jun, Susie·2013·British Journal of Haematology

Abstract

Summary: Romiplostim was effective, safe, and well‐tolerated over 6–12 months of continuous treatment in Phase 3 trials in patients with immune thrombocytopenia ( ITP ). This report describes up to 5 years of weekly treatment with romiplostim in 292 adult ITP patients in a long‐term, single‐arm, open‐label study. Outcome measures included adverse events (including bleeding, thrombosis, malignancy, and reticulin/fibrosis), platelet response (platelet count >50 × 10 9 per litre), and the proportion of patients requiring rescue treatments. Treatment–related serious adverse events were infrequent and did not increase with longer treatment. No new classes of adverse events emerged. Thrombotic events occurred in 6·5% of patients and were not associated with platelet count. Median platelet counts of 50–200 × 10 9 per litre were maintained with stable doses of romiplostim (mean 5–8 μg/kg; generally self‐administered at home) throughout the study. A platelet response was achieved at least once by 95% of patients, with a platelet response maintained by all patients on a median 92% of study visits. There was a low rate of bleeding and infrequent need for rescue treatments. In conclusion, this study demonstrated that romiplostim was safe and well‐tolerated over 614 patient‐years of exposure in ITP patients, and that efficacy was maintained with stable dosing for up to 5 years of continuous treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bjh.12260

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 275

Metadata

Authors
Kuter, D. J., Bussel, J. B., Newland, A., Baker, R. I., Lyons, R. M., Wasser, J., Viallard, J., Macik, G., Rummel, M., Nie, K., & Jun, S.
Venue
British Journal of Haematology
Publisher
Wiley
Published
2013-02-22
Volume
161
Issue
3
Pages
411-423
ISSN
  • 0007-1048 (ISSN-L)
  • 1365-2141
OpenAlex
W2033207183
Cited by
275
References
12
FWCI
19.20
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. https://app.cochat.ai/papers/10.1111/bjh.12260
The paper
Kuter, D. J., Bussel, J. B., Newland, A., Baker, R. I., Lyons, R. M., Wasser, J., Viallard, J., Macik, G., Rummel, M., Nie, K., & Jun, S. (2013). Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. British Journal of Haematology. https://doi.org/10.1111/bjh.12260

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.